The Impact of Antibiotic Use on Mortality in Patients Hospitalized in a COVID-19 Centre from Romania: A Retrospective Study.
COVID-19
antibiotic therapy
diabetes mellitus
female gender
heart failure
mortality
neoplasm history
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
11 Nov 2022
11 Nov 2022
Historique:
received:
15
09
2022
revised:
06
11
2022
accepted:
09
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Background and Objectives: Considering the significant number of patients worldwide that received empirical antibiotic therapy for COVID-19 infection due to their critical condition and the lack of therapeutical guidelines, we wanted to find out the consequences of antibiotic use in our study population. Materials and Methods: We conducted a retrospective cohort study including symptomatic patients older than 18 years, hospitalized for SARS-CoV-2 between March and December 2020 in the Internal Medicine and Pneumology Departments of Colentina Clinical Hospital. The elected outcome was death, while independent variables were antibiotic therapy and literature-cited parameters associated with mortality in this disease. Results: Out of 198 included patients, 96 (48.48%) patients received antibiotic therapy during hospitalization. Female gender (OR = 2.61, p = 0.04), history of neoplasm (OR = 7.147, p = 0.01), heart failure (OR = 8.62, p = 0.002), and diabetes mellitus (OR = 3.05, p = 0.02) were significantly associated with death in multivariate analysis. Antibiotic treatment showed a higher probability of death both in bivariate (OR = 5.333, p < 0.001) and multivariate analysis adjusted for the aforementioned prognostic factors (OR = 3.55, p = 0.01). Conclusions: After adjusting for confounders, in-hospital antibiotic administration did not improve survival in COVID-19 patients.
Identifiants
pubmed: 36422168
pii: medicina58111628
doi: 10.3390/medicina58111628
pmc: PMC9692657
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Immun Inflamm Dis. 2021 Dec;9(4):1648-1655
pubmed: 34438471
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2245-2249
pubmed: 33395786
J Clin Med. 2022 Jun 02;11(11):
pubmed: 35683579
Antibiotics (Basel). 2022 Jul 23;11(8):
pubmed: 35892381
Antibiotics (Basel). 2021 Jun 19;10(6):
pubmed: 34205440
J Osteopath Med. 2021 Sep 30;121(12):869-873
pubmed: 34592071
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Lancet Microbe. 2021 Aug;2(8):e354-e365
pubmed: 34100002
PLoS One. 2021 May 11;16(5):e0251340
pubmed: 33974637
J Intensive Care. 2020 Jul 10;8:49
pubmed: 32665858
J Pers Med. 2022 May 26;12(6):
pubmed: 35743662
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
BMC Infect Dis. 2021 Nov 8;21(1):1144
pubmed: 34749645
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
PLoS One. 2021 Aug 26;16(8):e0256744
pubmed: 34437642
PLoS One. 2021 Sep 10;16(9):e0256931
pubmed: 34506514
Intensive Care Med. 2021 Dec;47(12):1426-1439
pubmed: 34585270
Braz J Infect Dis. 2021 Mar-Apr;25(2):101569
pubmed: 33736948